[go: up one dir, main page]

AR004191A1 - POLYPEPTIDES TO INDUCE PROTECTIVE IMMUNITY AGAINST TUBERCULOSIS, DNA MOLECULES THAT CODES THEM, A VECTOR OF EXPRESSION, A HOST CELL, A VACCINE, A FUSION PROTEIN, A METHOD OF DETECTING TUBERCULOSIS - Google Patents

POLYPEPTIDES TO INDUCE PROTECTIVE IMMUNITY AGAINST TUBERCULOSIS, DNA MOLECULES THAT CODES THEM, A VECTOR OF EXPRESSION, A HOST CELL, A VACCINE, A FUSION PROTEIN, A METHOD OF DETECTING TUBERCULOSIS

Info

Publication number
AR004191A1
AR004191A1 ARP960104202A AR10420296A AR004191A1 AR 004191 A1 AR004191 A1 AR 004191A1 AR P960104202 A ARP960104202 A AR P960104202A AR 10420296 A AR10420296 A AR 10420296A AR 004191 A1 AR004191 A1 AR 004191A1
Authority
AR
Argentina
Prior art keywords
ala
pro
thr
ser
asp
Prior art date
Application number
ARP960104202A
Other languages
Spanish (es)
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of AR004191A1 publication Critical patent/AR004191A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un polipéptido caracterizado porque comprende una porción inmunogénica de un antígeno soluble de M.tuberculosis, ó una variante de dicho antígeno quedifiere sólo en sustituciones y/o modificaciones conservadoras, en el cual dicho antígeno tiene una secuencia de N-terminal seleccionado entre el grupoque consiste en: (a) Asp-Pro-Val-Asp-Ala-Val-Ile-Asn-Thr-Thr-Cys-Asn-Tyr-Gly-Gln-Val-Val-Ala-Ala-Leu (SEC.ID. N°120)(b) Ala-Val-Glu-Ser-Gly-Met-Leu-Ala-Leu-Gly-Thr-Pro-Ala-Pro-Ser (SEC.ID. N°121) (c) Ala-Ala-Met-Lys-Pro-Arg-Thr-Gly-Asp-Gly-Pro-Leu-Glu-Ala-Ala-Lys-Glu-Gly-Arg (SEC. ID. N°122) (d) Tyr-Tyr-Trp-Gys-Pro-Gly-Gln-Pro-Phe-Asp-Pro-Ala-Trp-Gly-Pro (SEC.ID. N°123)(e) Asp-Ile-Gly-Ser-Glu-Ser-Thr-Glu-Asp-Gln-Gln-Xaa-Ala-Val (SEC.ID.N°124) (f) Ala-Glu-Glu-Ser-Ile-Ser-Thr-Xaa-Glu-Xaa-Ile-Val-Pro (SEC.ID. N°125)(g) Asp-Pro-Glu-Pro-Ala-Pro-Pro-Val-Pro-Thr-Thr-Ala-Ala-Ser-Pro-Pro-Ser (SEC. ID N° |16)(h) Ala-Pro-Lys-Thr-Tyr-Naa-Glu-Glu-Leu-Lys-Gly-Thr-Asp-Thr-Gly (SEC.ID. N° 127)(i) Asp-Pro-Ala-Ser-Ala-Pro-Asp-Val-Pro-Thr-Ala-Ala-Gln-Leu-Thr-Ser-Leu-Leu- Asn-Ser-Leu-Ala-Asp-Pro-Asn-Val-Ser-Phe-Ala-Asn (SEC.ID. N° 128)(j) Xaa-Asp-Ser-Glu-Lys-Ser-Ala-Thr-Ile-Lys-Val-Thr-Asp-Ala-Ser (SEC.ID. N°134)donde Xaa puede ser cualquier aminoácido. Esos polipéptidos se pueden formular en vacunas y/o composiciones farmacéuticas para la inmunización contra laA polypeptide characterized in that it comprises an immunogenic portion of a soluble M. tuberculosis antigen, or a variant of said antigen that differs only in conservative substitutions and / or modifications, in which said antigen has an N-terminal sequence selected from the group consisting of in: (a) Asp-Pro-Val-Asp-Ala-Val-Ile-Asn-Thr-Thr-Cys-Asn-Tyr-Gly-Gln-Val-Val-Ala-Ala-Leu (SEQ ID N 120) (b) Ala-Val-Glu-Ser-Gly-Met-Leu-Ala-Leu-Gly-Thr-Pro-Ala-Pro-Ser (SEQ ID NO: 121) (c) Ala-Ala -Met-Lys-Pro-Arg-Thr-Gly-Asp-Gly-Pro-Leu-Glu-Ala-Ala-Lys-Glu-Gly-Arg (SEQ ID NO: 122) (d) Tyr-Tyr- Trp-Gys-Pro-Gly-Gln-Pro-Phe-Asp-Pro-Ala-Trp-Gly-Pro (SEQ ID NO: 123) (e) Asp-Ile-Gly-Ser-Glu-Ser-Thr -Glu-Asp-Gln-Gln-Xaa-Ala-Val (SEQ ID NO: 124) (f) Ala-Glu-Glu-Ser-Ile-Ser-Thr-Xaa-Glu-Xaa-Ile-Val- Pro (SEQ ID NO: 125) (g) Asp-Pro-Glu-Pro-Ala-Pro-Pro-Val-Pro-Thr-Thr-Ala-Ala-Ser-Pro-Pro-Ser (SEQ ID No. 16) (h) Ala-Pro-Lys-Thr-Tyr-Naa-Glu-Glu-Leu-Lys-Gly-Thr-Asp-Thr-Gly (SEQ ID NO: 12 7) (i) Asp-Pro-Ala-Ser-Ala-Pro-Asp-Val-Pro-Thr-Ala-Ala-Gln-Leu-Thr-Ser-Leu-Leu- Asn-Ser-Leu-Ala-Asp -Pro-Asn-Val-Ser-Phe-Ala-Asn (SEC.ID. No. 128) (j) Xaa-Asp-Ser-Glu-Lys-Ser-Ala-Thr-Ile-Lys-Val-Thr-Asp-Ala-Ser (SEC.ID. No. 134) where Xaa can be any amino acid. Those polypeptides can be formulated into vaccines and / or pharmaceutical compositions for immunization against

ARP960104202A 1995-09-01 1996-09-02 POLYPEPTIDES TO INDUCE PROTECTIVE IMMUNITY AGAINST TUBERCULOSIS, DNA MOLECULES THAT CODES THEM, A VECTOR OF EXPRESSION, A HOST CELL, A VACCINE, A FUSION PROTEIN, A METHOD OF DETECTING TUBERCULOSIS AR004191A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52343695A 1995-09-01 1995-09-01
US53363495A 1995-09-22 1995-09-22
US62087496A 1996-03-22 1996-03-22

Publications (1)

Publication Number Publication Date
AR004191A1 true AR004191A1 (en) 1998-11-04

Family

ID=51983135

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960104202A AR004191A1 (en) 1995-09-01 1996-09-02 POLYPEPTIDES TO INDUCE PROTECTIVE IMMUNITY AGAINST TUBERCULOSIS, DNA MOLECULES THAT CODES THEM, A VECTOR OF EXPRESSION, A HOST CELL, A VACCINE, A FUSION PROTEIN, A METHOD OF DETECTING TUBERCULOSIS

Country Status (1)

Country Link
AR (1) AR004191A1 (en)

Similar Documents

Publication Publication Date Title
DE60332645D1 (en) II-KEY / ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINE
NO20070621L (en) Compounds and Methods for Immunotherapy and Diagnosis of Tuberculosis
AR008727A1 (en) COMPOSITIONS AND MELTING PROTEINS INCLUDING A POLYPEPTIDE INCLUDING AN IMMUNOGENIC PORTION OF A PROSTATE PROTEIN OR ITS VARIANT, AND USES THEREOF TO PREPARE A MEDICINAL PRODUCT
ATE269100T1 (en) METHOD FOR THERAPEUTIC VACCINATION
BR9809445A (en) Polypeptide comprising an immunogenic portion of a m antigen. tubercolosis, dna molecule, expression vector, host cell, pharmaceutical composition, vaccine, fusion protein, processes for inducing protective immunity in a patient, tuberculosis detection process in a patient, and, diagnostic kit.
NO984244L (en) Vaccine Compositions and Methods Useful in Inducing Immune Protection against Arthritogenic Peptides Involved in Pathogenesis of Rheumatoid Arthritis
AR020066A1 (en) A PURIFIED POLYPEPTIDE, USEFUL TO PREVENT TUBERCULOSIS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE POLYPEPTIDES AND THE POLYCUCLEOTIDES WHICH CODIFY
DE69836520D1 (en) Clostridium perfringens vaccine
WO2003090667A3 (en) Non-immunosuppressive imunogenic or vaccine composition comprising a mutated e7 protein of the hpv-16 virus
AR004191A1 (en) POLYPEPTIDES TO INDUCE PROTECTIVE IMMUNITY AGAINST TUBERCULOSIS, DNA MOLECULES THAT CODES THEM, A VECTOR OF EXPRESSION, A HOST CELL, A VACCINE, A FUSION PROTEIN, A METHOD OF DETECTING TUBERCULOSIS
WO2023038961A3 (en) Common cold coronavirus t cell epitopes, methods and uses thereof
PE20010237A1 (en) GENE DERIVED FROM LAWSONIA AND OmpH POLYPEPTIDES, PEPTIDES AND RELATED PROTEINS AND THEIR USES
NZ515041A (en) Nucleic acid immunization
PE20010316A1 (en) GENE DERIVED FROM LAWSONIA AND RELATED POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES
ES2308850T3 (en) ANTIBODIES FOR ANTIGENS OF CELLS OF LANGERHANS OF MAMIFEROS AND ITS USES.
NO20011263D0 (en) Moraxella Catarrhalis BASBO34 polypeptides and uses thereof
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
AR004190A1 (en) POLYPEPTIDES TO DIAGNOSE TUBERCULOSIS, A DNA MOLECULES THAT CODES THEM, A VECTOR OF EXPRESSION, A CELL HOST, A METHOD FOR DETECTARTUBERCULOSIS, A DIAGNOSTIC KIT, A MONOCLONAL ANTIBODY AND PROTEIN.
AR012896A1 (en) HELICOBACTER PYLORI FLGE POLYPEPTIDE, VACCINE COMPOSITION, USE OF SUCH POLYPEPTIDE FOR THE MANUFACTURE OF COMPOSITIONS, INVITRO DIAGNOSTIC METHOD AND DIAGNOSTIC KIT FOR THE DETECTION OF HELICOBACTER PYLORI INFECTION
BR0016740A (en) Cryptosporidium sporozoite antigens
WO2004056316A3 (en) Vaccines against hiv-1 tat protein to generate neutralizing antibodies
CO4560555A1 (en) TUBERCULOSIS IMMUNOTHERAPY AND DIAGNOSTIC COMPOUNDS
AR009840A1 (en) VACCINE PREPARATION FOR REVESIBLE IMMUNOCASTRATION OF MAMMALS
ATE305941T1 (en) VACCINE
ATE480250T1 (en) NEW TRP2 ISOFORM WITH CYTOTOXIC T-LYMPHOCYTE EPITOPES WITH HLA-A2 RESTRICTION